Palvella Therapeutics
PVLA
100 hedge funds and large institutions have $534M invested in Palvella Therapeutics in 2025 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 9 closing their positions.
367% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 9
301% more capital invested
Capital invested by funds: $133M → $534M (+$401M)
208% more call options, than puts
Call options by funds: $984K | Put options by funds: $320K
49% more funds holding
Funds holding: 67 → 100 (+33)
23.63% more ownership
Funds ownership: 53.45% → 77.09% (+24%)
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$24.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$20.7M |
| 3 |
PA
Perceptive Advisors
New York
|
+$17.6M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$15.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$12.8M |
| 2 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$6.74M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$5.8M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$4.45M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.07M |
PVLA Hedge Fund Activity: Q3 2025 in Review
100 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2025, worth a combined $534M — up 301% from $133M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new PVLA positions and 9 closed out — a net gain of 33 holders — while 24 added to existing stakes and 20 trimmed.
The largest buyer was First Light Asset Management, opening a new position worth an estimated $24.1M. The largest seller was Millennium Management, cutting an estimated $12.8M.
- 100 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2025, up from 67 in Q2 2025.
- Funds reported $534M of Palvella Therapeutics stock for Q3 2025, up 301% quarter-over-quarter.
- 42 funds opened new Palvella Therapeutics positions in Q3 2025 and 9 closed out, a net change of +33 holders.
- The largest Palvella Therapeutics buyer in Q3 2025 was First Light Asset Management, an estimated $24.1M added.
- The largest Palvella Therapeutics seller in Q3 2025 was Millennium Management, an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2025.